This article is more than 5 years old. Information may no longer be current.
Anti-VEGF therapy may prevent progression of nonsubfoveal neovascularization to subfoveal area
Retina. 2009;29(10):1444-1449.
Click Here to Manage Email Alerts
Anti-VEGF therapy may be beneficial for treatment of nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration, especially in preventing progression of lesions to a subfoveal location.
According to a retrospective, multicenter, noncomparative, interventional case series in 15 patients with a mean age of 72.4 years who were treated with Lucentis (ranibizumab, Genentech) for treatment-naïve nonsubfoveal choroidal neovascularization secondary to AMD, mean visual acuity improved from 20/60 at baseline to 20/40 at 1 year. In addition, mean foveal thickness decreased from 312 µm at baseline to 262 µm.
Of the 15 patients, nine had improvement in visual acuity by the end of the study, five had unchanged vision and one had worse vision. Vision improved in all patients with visual acuity of 20/40 or better at baseline.
Mean lesion size was 1.9 disc areas at baseline and 1.1 disc areas at 1 year; small initial lesion size could be an important factor in response to therapy, the study authors noted.